{"pmid":32399806,"title":"Is COVID-19 a New Hematologic Disease?","text":["Is COVID-19 a New Hematologic Disease?","SARS-CoV-2 viruses are positive single-stranded RNA viruses, whose infection can be asymptomatic or lead to the coronavirus disease 2019 (Covid-19). Covid-19 is a respiratory infection with a significant impact on the hematopoietic system and hemostasis leading to several cardiovascular complications. Hematologic consequences of this new infection allowed medical community to start new treatment approaches concerning infection going from targeted anti-inflammatory drugs to anticoagulation or stem cell therapies. A better understanding of Covid-19 pathophysiology, in particular hematological disorders, will help to choose appropriate treatment strategies.","Stem Cell Rev Rep","Debuc, Benjamin","Smadja, David M","32399806"],"abstract":["SARS-CoV-2 viruses are positive single-stranded RNA viruses, whose infection can be asymptomatic or lead to the coronavirus disease 2019 (Covid-19). Covid-19 is a respiratory infection with a significant impact on the hematopoietic system and hemostasis leading to several cardiovascular complications. Hematologic consequences of this new infection allowed medical community to start new treatment approaches concerning infection going from targeted anti-inflammatory drugs to anticoagulation or stem cell therapies. A better understanding of Covid-19 pathophysiology, in particular hematological disorders, will help to choose appropriate treatment strategies."],"journal":"Stem Cell Rev Rep","authors":["Debuc, Benjamin","Smadja, David M"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32399806","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s12015-020-09987-4","keywords":["coagulopathy","covid-19","cytokine","d-dimers","inflammation","lymphopenia","mesenchymal stem cells","sars-cov-2","stem cells","thrombosis"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666865855078596609,"score":9.490897,"similar":[{"pmid":32420049,"pmcid":"PMC7224671","title":"Combating COVID-19 with Mesenchymal Stem Cell therapy.","text":["Combating COVID-19 with Mesenchymal Stem Cell therapy.","The COVID-19 disease is caused by a positive stranded RNA virus called SARS-CoV-2. The virus mainly targets the pulmonary epithelial cells as it's initial site of infection by letting its surface spike protein interact and bind to the host ACE2 receptor. The internalization and gradual replication of the virus results in an exaggerated immune response triggering release of many pro-inflammatory cytokines and chemokines. This immune storm is responsible for multiple health hazards in the host ultimately leading to multiple organ failure. Mesenchymal stem cell therapy offers a promising approach towards mitigating the delirious effects of the infection in the COVID-19 patients. This therapy has shown to reduce the expression of pro-inflammatory cytokines as well as repair of damaged tissues in COVID-19 patients. This review has been organized to put forward the positive aruments and implications in support of mesenchymal stem cell therapy as a necessary approach for treating COVID-19 patients.","Biotechnol Rep (Amst)","Rajarshi, Keshav","Chatterjee, Aroni","Ray, Shashikant","32420049"],"abstract":["The COVID-19 disease is caused by a positive stranded RNA virus called SARS-CoV-2. The virus mainly targets the pulmonary epithelial cells as it's initial site of infection by letting its surface spike protein interact and bind to the host ACE2 receptor. The internalization and gradual replication of the virus results in an exaggerated immune response triggering release of many pro-inflammatory cytokines and chemokines. This immune storm is responsible for multiple health hazards in the host ultimately leading to multiple organ failure. Mesenchymal stem cell therapy offers a promising approach towards mitigating the delirious effects of the infection in the COVID-19 patients. This therapy has shown to reduce the expression of pro-inflammatory cytokines as well as repair of damaged tissues in COVID-19 patients. This review has been organized to put forward the positive aruments and implications in support of mesenchymal stem cell therapy as a necessary approach for treating COVID-19 patients."],"journal":"Biotechnol Rep (Amst)","authors":["Rajarshi, Keshav","Chatterjee, Aroni","Ray, Shashikant"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420049","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.btre.2020.e00467","keywords":["covid-19","cytokines","immunomodulatory","mesenchymal stem cells","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667159284484407296,"score":172.02495},{"pmid":32228226,"pmcid":"PMC7170362","title":"Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients.","text":["Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients.","Circulating in China and 158 other countries and areas, the ongoing COVID-19 outbreak has caused devastating mortality and posed a great threat to public health. However, efforts to identify effectively supportive therapeutic drugs and treatments has been hampered by our limited understanding of host immune response for this fatal disease. To characterize the transcriptional signatures of host inflammatory response to SARS-CoV-2 (HCoV-19) infection, we carried out transcriptome sequencing of the RNAs isolated from the bronchoalveolar lavage fluid (BALF) and peripheral blood mononuclear cells (PBMC) specimens of COVID-19 patients. Our results reveal distinct host inflammatory cytokine profiles to SARS-CoV-2 infection in patients, and highlight the association between COVID-19 pathogenesis and excessive cytokine release such as CCL2/MCP-1, CXCL10/IP-10, CCL3/MIP-1A, and CCL4/MIP1B. Furthermore, SARS-CoV-2 induced activation of apoptosis and P53 signalling pathway in lymphocytes may be the cause of patients' lymphopenia. The transcriptome dataset of COVID-19 patients would be a valuable resource for clinical guidance on anti-inflammatory medication and understanding the molecular mechansims of host response.","Emerg Microbes Infect","Xiong, Yong","Liu, Yuan","Cao, Liu","Wang, Dehe","Guo, Ming","Jiang, Ao","Guo, Dong","Hu, Wenjia","Yang, Jiayi","Tang, Zhidong","Wu, Honglong","Lin, Yongquan","Zhang, Meiyuan","Zhang, Qi","Shi, Mang","Liu, Yingle","Zhou, Yu","Lan, Ke","Chen, Yu","32228226"],"abstract":["Circulating in China and 158 other countries and areas, the ongoing COVID-19 outbreak has caused devastating mortality and posed a great threat to public health. However, efforts to identify effectively supportive therapeutic drugs and treatments has been hampered by our limited understanding of host immune response for this fatal disease. To characterize the transcriptional signatures of host inflammatory response to SARS-CoV-2 (HCoV-19) infection, we carried out transcriptome sequencing of the RNAs isolated from the bronchoalveolar lavage fluid (BALF) and peripheral blood mononuclear cells (PBMC) specimens of COVID-19 patients. Our results reveal distinct host inflammatory cytokine profiles to SARS-CoV-2 infection in patients, and highlight the association between COVID-19 pathogenesis and excessive cytokine release such as CCL2/MCP-1, CXCL10/IP-10, CCL3/MIP-1A, and CCL4/MIP1B. Furthermore, SARS-CoV-2 induced activation of apoptosis and P53 signalling pathway in lymphocytes may be the cause of patients' lymphopenia. The transcriptome dataset of COVID-19 patients would be a valuable resource for clinical guidance on anti-inflammatory medication and understanding the molecular mechansims of host response."],"journal":"Emerg Microbes Infect","authors":["Xiong, Yong","Liu, Yuan","Cao, Liu","Wang, Dehe","Guo, Ming","Jiang, Ao","Guo, Dong","Hu, Wenjia","Yang, Jiayi","Tang, Zhidong","Wu, Honglong","Lin, Yongquan","Zhang, Meiyuan","Zhang, Qi","Shi, Mang","Liu, Yingle","Zhou, Yu","Lan, Ke","Chen, Yu"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32228226","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1080/22221751.2020.1747363","keywords":["covid-19","cytokine","inflammation","lymphopenia","transcriptome profiling"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138492195831810,"score":164.62637},{"pmid":32348044,"title":"[Hematology in the time of COVID-19].","text":["[Hematology in the time of COVID-19].","The COVID-19 pandemic impacts the hematology practice. Intensive chemotherapies for high-grade lymphomas and acute leukemias, multiple myeloma treatments and most hematopoietic stem cell transplantations should be performed as usual. Low-grade lymphomas should only be treated when strictly indicated, maintenance can be postponed. Other myeloid neoplasia and their therapies cause imunosupression; dose adjustment is recommended but no brisk stopping. Sickle cell anemia patients are highly succeptible to severe COVID-19 course. Thrombocytopenia and procoagulant state are associated with severe courses of COVID-19, requiring an individualized therapy. No data indicate a risk of SARS-CoV-2 transmission through blood product transfusion.","Rev Med Suisse","Gavillet, Mathilde","Rufer, Nathalie","Grandoni, Francesco","Carr Klappert, Jeanette","Zermatten, Maxime G","Cairoli, Anne","Canellini, Giorgia","Alberio, Lorenzo","Duchosal, Michel A","Spertini, Olivier","Blum, Sabine","32348044"],"abstract":["The COVID-19 pandemic impacts the hematology practice. Intensive chemotherapies for high-grade lymphomas and acute leukemias, multiple myeloma treatments and most hematopoietic stem cell transplantations should be performed as usual. Low-grade lymphomas should only be treated when strictly indicated, maintenance can be postponed. Other myeloid neoplasia and their therapies cause imunosupression; dose adjustment is recommended but no brisk stopping. Sickle cell anemia patients are highly succeptible to severe COVID-19 course. Thrombocytopenia and procoagulant state are associated with severe courses of COVID-19, requiring an individualized therapy. No data indicate a risk of SARS-CoV-2 transmission through blood product transfusion."],"journal":"Rev Med Suisse","authors":["Gavillet, Mathilde","Rufer, Nathalie","Grandoni, Francesco","Carr Klappert, Jeanette","Zermatten, Maxime G","Cairoli, Anne","Canellini, Giorgia","Alberio, Lorenzo","Duchosal, Michel A","Spertini, Olivier","Blum, Sabine"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348044","source":"PubMed","week":"202018|Apr 27 - May 03","locations":["Thrombocytopenia"],"topics":["Transmission","Treatment","Prevention"],"weight":1,"_version_":1666138494954635267,"score":149.36539},{"pmid":32299202,"title":"COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs","text":["COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs","In the Wuhan Province of China, in December 2019, the novel coronavirus 2019 (COVID-19) has caused a severe involvement of the lower respiratory tract leading to an acute respiratory syndrome. Subsequently, coronavirus 2 (SARS-CoV-2) provoked a pandemic which is considered a life-threatening disease. The SARS-CoV-2, a family member of betacoronaviruses, possesses single-stranded positive-sense RNA with typical structural proteins, involving the envelope, membrane, nucleocapsid and spike proteins that are responsible for the viral infectivity, and nonstructural proteins. The effectual host immune response including innate and adaptive immunity against SARS-Cov-2 seems crucial to control and resolve the viral infection. However, the severity and outcome of the COVID-19 might be associated with the excessive production of proinflammatory cytokines \"cytokine storm\" leading to an acute respiratory distress syndrome. Regretfully, the exact pathophysiology and treatment, especially for the severe COVID-19, is still uncertain. The results of preliminary studies have shown that immune-modulatory or immune-suppressive treatments such as hydroxychloroquine, interleukin (IL)-6 and IL-1 antagonists, commonly used in rheumatology, might be considered as treatment choices for COVID-19, particularly in severe disease. In this review, to gain better information about appropriate anti-inflammatory treatments, mostly used in rheumatology for COVID-19, we have focused the attention on the structural features of SARS-CoV-2, the host immune response against SARS-CoV-2 and its association with the cytokine storm.","Turk J Med Sci","Tufan, Abdurrahman","Avanoglu Guler, Aslihan","Matucci-Cerinic, Marco","32299202"],"abstract":["In the Wuhan Province of China, in December 2019, the novel coronavirus 2019 (COVID-19) has caused a severe involvement of the lower respiratory tract leading to an acute respiratory syndrome. Subsequently, coronavirus 2 (SARS-CoV-2) provoked a pandemic which is considered a life-threatening disease. The SARS-CoV-2, a family member of betacoronaviruses, possesses single-stranded positive-sense RNA with typical structural proteins, involving the envelope, membrane, nucleocapsid and spike proteins that are responsible for the viral infectivity, and nonstructural proteins. The effectual host immune response including innate and adaptive immunity against SARS-Cov-2 seems crucial to control and resolve the viral infection. However, the severity and outcome of the COVID-19 might be associated with the excessive production of proinflammatory cytokines \"cytokine storm\" leading to an acute respiratory distress syndrome. Regretfully, the exact pathophysiology and treatment, especially for the severe COVID-19, is still uncertain. The results of preliminary studies have shown that immune-modulatory or immune-suppressive treatments such as hydroxychloroquine, interleukin (IL)-6 and IL-1 antagonists, commonly used in rheumatology, might be considered as treatment choices for COVID-19, particularly in severe disease. In this review, to gain better information about appropriate anti-inflammatory treatments, mostly used in rheumatology for COVID-19, we have focused the attention on the structural features of SARS-CoV-2, the host immune response against SARS-CoV-2 and its association with the cytokine storm."],"journal":"Turk J Med Sci","authors":["Tufan, Abdurrahman","Avanoglu Guler, Aslihan","Matucci-Cerinic, Marco"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32299202","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.3906/sag-2004-168","keywords":["covid-19","cytokine storm","inflammation","rheumatology","treatment","antiinflammatory"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Hydroxychloroquine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494766940161,"score":139.4017},{"pmid":32458561,"title":"Lymphopenia in COVID-19: Therapeutic Opportunities.","text":["Lymphopenia in COVID-19: Therapeutic Opportunities.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is uncontrollably spread all over the world. The host immune responses strongly try to confront it with all the potential cells and cytokines. With chronically condition of SARS-CoV-2, NK cells and T cells become exhausted and decreasing their count leads to lymphopenia. Inability to eradicate the infected organ makes hyper-initiation of the immune system, which releases the excessive inflammatory cytokines to compensate the exhausted one as well as the low lymphocytes counts; it consequently lead to the cytokine storm syndrome. These mechanisms and the potential therapeutic targeting are discussed in this paper. This article is protected by copyright. All rights reserved.","Cell Biol Int","Fathi, Nazanin","Rezaei, Nima","32458561"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is uncontrollably spread all over the world. The host immune responses strongly try to confront it with all the potential cells and cytokines. With chronically condition of SARS-CoV-2, NK cells and T cells become exhausted and decreasing their count leads to lymphopenia. Inability to eradicate the infected organ makes hyper-initiation of the immune system, which releases the excessive inflammatory cytokines to compensate the exhausted one as well as the low lymphocytes counts; it consequently lead to the cytokine storm syndrome. These mechanisms and the potential therapeutic targeting are discussed in this paper. This article is protected by copyright. All rights reserved."],"journal":"Cell Biol Int","authors":["Fathi, Nazanin","Rezaei, Nima"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32458561","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/cbin.11403","keywords":["apoptosis","covid-19","coronavirus","cytokine storm syndrome","hypercytokinemia","inflammation","lymphopenia","therapeutic"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667967698924994560,"score":136.92407}]}